BridgeBio Oncology Therapeutics

(NASDAQ) BBOT

Current Price$9.00

Market Cap$705.74M

Since IPO (2024)-14%

5 YearN/A

1 YearN/A

1 Month-5%

BridgeBio Oncology Therapeutics Financials at a Glance

Market Cap

$705.74M

Revenue (TTM)

$0.00

Net Income (TTM)

$154.09M

EPS (TTM)

$-527.59

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

2.21 (High)

Dividend

$0.00

Beta (Volatility)

2.21 (High)

Price

$9.00

Volume

3,578

Open

$8.71

Price

$9.00

Volume

3,578

Open

$8.71

Previous Close

$8.81

Daily Range

$8.71 - $9.01

52-Week Range

$7.60 - $14.87

Dividend

$0.00

Beta (Volatility)

2.21 (High)

Price

$9.00

Volume

3,578

Open

$8.71

Previous Close

$8.81

Daily Range

$8.71 - $9.01

52-Week Range

$7.60 - $14.87

BBOT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BridgeBio Oncology Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Eli M. Wallace, PhD

Website

bbotx.com

Headquarters

South San Francisco, CA 94080, US

BBOT Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-45%

Return on Capital

-45%

Return on Assets

-37%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$705.74M

Shares Outstanding

80.11M

Volume

3.58K

Avg. Volume

336.91K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$145.82M

EBITDA

$145.21M

Operating Cash Flow

$113.89M

Capital Expenditure

$606.00K

Free Cash Flow

$114.50M

Cash & ST Invst.

$425.46M

Total Debt

$2.77M

BridgeBio Oncology Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$186.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$705.74M

N/A

Market Cap/Employee

$11.38M

N/A

Employees

N/A

Net Income

$42.11M

-90.9%

EBITDA

$45.99M

-99.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$249.63M

+87.6%

Accounts Receivable

$146.00K

+265.0%

Inventory

$0.00

N/A

Long Term Debt

$2.11M

-20.3%

Short Term Debt

$538.00K

+8866.7%

Return on Assets

-36.90%

N/A

Return on Invested Capital

-45.10%

N/A

Free Cash Flow

$35.94M

-4792.3%

Operating Cash Flow

$35.92M

-4789.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

XNCRXencor, Inc.

XNCRXencor, Inc.$11.37+0.45%

PHATPhathom Pharmaceuticals, Inc.

PHATPhathom Pharmaceuticals, Inc.$11.58-2.44%

SEPNSepterna, Inc.

SEPNSepterna, Inc.$27.89-0.41%

URGNUroGen Pharma Ltd.

URGNUroGen Pharma Ltd.$29.91-1.03%

NRIXNurix Therapeutics, Inc.

NRIXNurix Therapeutics, Inc.$17.05+3.87%

OCSOculis Holding AG

OCSOculis Holding AG$30.71+10.02%

KODKodiak Sciences Inc.

KODKodiak Sciences Inc.$36.29+0.20%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.74+0.00%

TET1 Energy Inc.

TET1 Energy Inc.$9.20+0.06%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$75.69-0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.66+0.01%

RGTZTidal Trust II - Defiance Daily Target 2x Short Rgti ETF

RGTZTidal Trust II - Defiance Daily Target 2x Short Rgti ETF$6.05-0.51%

APLDApplied Digital

APLDApplied Digital$47.17+0.19%

RGTIRigetti Computing

RGTIRigetti Computing$21.35+0.26%

Questions About BBOT

What is the current price of BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics is trading at $9.00 per share.

What is the 52-week range for BridgeBio Oncology Therapeutics?

Over the past 52 weeks, BridgeBio Oncology Therapeutics has traded between $7.60 and $14.87.

How much debt does BridgeBio Oncology Therapeutics have?

As of the most recent reporting period, BridgeBio Oncology Therapeutics reported total debt of $2.64M.

How much cash does BridgeBio Oncology Therapeutics have on hand?

BridgeBio Oncology Therapeutics reported $52.66M in cash and cash equivalents in its most recent financial results.

What is BridgeBio Oncology Therapeutics’s dividend yield?

BridgeBio Oncology Therapeutics does not currently have a dividend yield.

BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics Financials at a Glance

BBOT News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About BridgeBio Oncology Therapeutics

BBOT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

BridgeBio Oncology Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BBOT

What is the current price of BridgeBio Oncology Therapeutics?

What is the 52-week range for BridgeBio Oncology Therapeutics?

How much debt does BridgeBio Oncology Therapeutics have?

How much cash does BridgeBio Oncology Therapeutics have on hand?

What is BridgeBio Oncology Therapeutics’s dividend yield?

Premium Investing Services